Chief Scientific Officer, Peplin, Inc.
| Role | Organisation | Sources |
|---|---|---|
| Chief Scientific Officer | Peplin, Inc. | GBS Ventures (12 Nov 2009), GBS Ventures (8 Jan 2009) |
Stories naming Dr Peter Welburn. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
LEO Pharma's acquisition of Peplin is done, a deal agreed in September 2009 for about US$287.5 million. Peplin continues as a LEO subsidiary led by chief executive George Mahaffey, keeping Australian operations.
Also GBS Ventures
A Brisbane skin-cancer biotech reports successful late-stage results for its sun-spot gel, saying it remains on schedule for a US regulatory filing and a 2011 market launch.
Peplin reports its PEP005 gel met the primary endpoint in a Phase IIb actinic keratosis trial, clearing lesions safely across doses and moving toward Phase III development.